Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to SARS-CoV-2

Douglas F. Lake; Alexa J. Roeder; Erin Kaleta; Paniz Jasbi; Kirsten Pfeffer; Calvin J Koelbel; Sivakumar Periasamy; Natalia Kuzmina; Alexander Bukreyev; Thomas E Grys; Liang Wu; John R. Mills; Kathrine McAulay; Alim Seit-Nebi; Sergei Svarovsky.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-20248264

Documentos relacionados

  1. Development of a rapid point-of-care test that measures neutralizing antibodies to SARS-CoV-2.
  2. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
  3. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  4. Neutralization of SARS-CoV-2 requires antibodies against conformational receptor-binding domain epitopes.
  5. Myeloid dysregulation and therapeutic intervention in COVID-19.
  6. Dissecting the intricacies of human antibody responses to SARS-CoV-1 and SARS-CoV-2 infection.
  7. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.
  8. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting.
  9. Immune evasion, infectivity, and fusogenicity of SARS-CoV-2 BA.2.86 and FLip variants.
  10. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization.